SEC Form 4	
------------	--

Instruction 1(b).

FORM 4

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

OMB APPROVAL

L		• • • • •								
	OMB Number:	3235-0287								
	Estimated average burden									
	hours per response:	0.5								

STATEMENT	OF	CHANGES	IN	BENEFICIAL	OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Addre	1 0		2. Issuer Name and Ticker or Trading Symbol KalVista Pharmaceuticals, Inc. [KALV]	5. Relationship of Reporting Person(s) to Issuer (Check all applicable)				
Crockett Thomas Andrew			[X	Director	10% Owner		
(Last) (First) (Middle) C/O KALVISTA PHARMACEUTICALS, INC.		, ,	3. Date of Earliest Transaction (Month/Day/Year) 02/01/2024	X	Officer (give title below)	Other (specify below)		
55 CAMBRIDGE PARKWAY, SUITE 901E			4. If Amendment, Date of Original Filed (Month/Day/Year)	6. Individual or Joint/Group Filing (Check Applicable Line)				
(Street)				X	Form filed by One Rep	orting Person		
CAMBRIDGE	MA	02142			Form filed by More that Person	in One Reporting		
(City)	(State)	(Zip)	Rule 10b5-1(c) Transaction Indication					
	Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan that is inter- satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.							

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned

1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Transaction Disposed Of (D) (Instr. 3, 4 and 5) Code (Instr. 8)		on Disposed Of (D) (Instr. 3, 4 and 5)		Disposed Of (D) (Instr. 3, 4 and 5) Securities F Beneficially (I Owned Following In		Form: Direct (D) or Indirect (I)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	v	Amount	(A) or (D)	Price	Transaction(s) (Instr. 3 and 4)	(Instr. 4)	(1150. 4)
Common Stock	02/01/2024		S ⁽¹⁾		9,300	D	\$ 16.1751 ⁽²⁾	118,232	D	
Common Stock	02/01/2024		S ⁽¹⁾		700	D	\$16.8143 ⁽³⁾	117,532	D	

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned

(e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)		saction of		Transaction Code (Instr. 8) Acquired (A) or Disposed of (D) (Instr. 3, 4		rities lired r osed) r. 3, 4	6. Date Exercisable and Expiration Date (Month/Day/Year)		Expiration Date (Month/Day/Year) eed sed 3, 4		d 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	v	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares								

Explanation of Responses:

1. The transactions reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on January 31, 2023.

2. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from \$15.77 to \$16.71, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth herein.

3. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from \$16.77 to \$16.87, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth herein.

/s/ Benjamin L. Palleiko,	
Attorney-in-Fact	

<u>02/05/2024</u>

** Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.